natgillin/translations-raw huggingface dataset:
Samlede resultater fra de tre behandlingsniveauer
Pooled results across the 3 treatment levels
Samleje uden latexkondom
Sexual intercourse without a latex condom
SAMLET
POOLED
Samlet (ITT)
Overall
Samlet (N=411)
Overall (N=411)
Samlet antal nonrespondere* i uge 120
Overall non-responder* at Week 120
Samlet antal nonrespondere* i uge 24
Overall non- responder* at Week 24
Samlet antal patienter, der indtrådte i fasen med antiviral behandling
Total number of patients entering Antiviral Treatment Phase
Samlet antal respondere i uge 120
Overall responder at Week 120
Samlet antal respondere i uge 24
Overall responder at Week 24
Samlet antal virologiske svigta, n (%)
Total number of virologic failuresa, n (%)
Samlet antal virologiske svigta, n(%)
Total number of virologic failuresa, n (%)
Samlet antal VTE’er
Total VTE
Samlet blev 392/3.095 (12,7 %) af patienterne med reumatoid artrit testet positive for HACA i kliniske studier efter behandling med MabThera.
A total of 392/3095 (12.7%) patients with rheumatoid arthritis tested positive for HACA in clinical studies following therapy with MabThera.
Samlet blev de fleste bivirkninger anset for at være lette til moderate i sværhedsgrad.
Overall, most adverse reactions were considered to be mild or moderate in severity.
Samlet celleantal: x 106
Total cell number: x 106
Samlet daglig dosis levodopa (mg) i levodopa/DDC- hæmmer/entacapon
Total daily dose of levodopa (mg) in levodopa/DDC inhibitor/entacapone
Samlet daglig dosis levodopa i levodopa/DDC- hæmmer med øjeblikkelig udløsning (mg)
Total daily dose of levodopa in immediate release levodopa/DDC inhibitor (mg)
Samlet daglig dosis RAVICTI (ml) = samlet daglig dosis natriumphenylbutyrat-pulver (g) x 0,81
Total daily dosage of RAVICTI (ml) = total daily dosage of sodium phenylbutyrate powder (g) x 0.81
Samlet daglig dosis RAVICTI (ml) = samlet daglig dosis natriumphenylbutyrat-tabletter (g) x 0,86
Total daily dosage of RAVICTI (ml) = total daily dosage of sodium phenylbutyrate tablets (g) x 0.86
Samlet daglig dosis sevelamercarbonat fordelt på 3 måltider
Total daily dose of sevelamer carbonate to be taken over 3 meals per day
Samlet dosis (mg) tenofovirdisoproxil (som fumarat)
Total dose (mg) tenofovir disoproxil (as fumarate)
Samlet dosis (mg/dag)
Total dose (mg/day)
Samlet effektanalyse
Pooled Efficacy Analysis
Samlet er de afledte data fra denne studie for begrænsede til at drage definitive konklusioner om sammenligningen mellem emtricitabin plus tenofovirdisoproxilfumarat og tenofovirdisoproxilfumarat (se tabel 7 nedenunder).
Overall, the data derived from this study are too limited to draw any definitive conclusions on the comparison of emtricitabine plus tenofovir disoproxil fumarate versus tenofovir disoproxil fumarate, (see Table 7 below).
Samlet er de afledte data fra denne studie for begrænsede til at drage definitive konklusioner om sammenligningen mellem emtricitabin plus tenofovirdisoproxilfumarat og tenofovirdisoproxilfumarat (se tabel 8 nedenunder).
Overall, the data derived from this study are too limited to draw any definitive conclusions on the comparison of emtricitabine plus tenofovir disoproxil fumarate versus tenofovir disoproxil fumarate, (see Table 8 below).
Samlet er der ikke observeret forskelle med hensyn til effekt og sikkerhed hos patienter på 65 år eller ældre, som fik Stelara, sammenlignet med yngre patienter, men antallet af patienter i alderen 65 år og derover er dog ikke tilstrækkeligt til at fastslå, om de reagerer anderledes end yngre patienter.
No overall differences in efficacy or safety in patients age 65 and older who received STELARA were observed compared to younger patients, however the number of patients aged 65 and older is not sufficient to determine whether they respond differently from younger patients.
Samlet fase
Overall phase
Samlet fase§
Overall phase§
Samlet frekvens af alle CTCAE-grader
Frequency of All CTCAE grades
Samlet frekvens af partielle anfald (median), ændring i %
Total partial seizure frequency (median) % change
Samlet havde 7% af mRCC-populationen enten kliniske eller laboratoriemæssige tegn på behandlingsprovokeret hypotyreose.
Overall, 7% of the MRCC population had either clinical or laboratory evidence of treatment-emergent hypothyroidism.
Samlet hazard ratio (95%CI)*
Overall hazard ratio (95%CI)
Samlet hyppighed
Frequency overall
Samlet komplet respons (CR+CRu)f n(%)
Overall complete response (CR+CRu)f n(%)
Samlet kropsvægt af kyllinger, der skal behandles
Total body weight of chickens to be treated
Samlet liste over bivirkninger: Meget almindelig:
Overall list of possible side effects: Very common:
Samlet mortalitet i studiet
Overall study mortality
Samlet målopfyldelse (%)
Partial Response
Samlet mængde (ml) Vimizim divideret med 5 ml pr. hætteglas = samlet antal hætteglas
Total amount (ml) Vimizim divided by 5 ml per vial = Total number of vials
Samlet nåede 76 % af patienterne op på Neparvis’ måldosis 200 mg to gange daglig og kunne vedligeholde den uden afbrydelse eller nedtitrering i studieperioden på 12 uger.
Overall, 76% of patients achieved and maintained the target dose of Neparvis 200 mg twice daily without any dose interruption or down-titration over 12 weeks.
Samlet oplevede 5,8 % af patienterne en stigning i indirekte bilirubin > 1- 2 gange øvre normalgrænse, og 0,4 % havde en stigning på > 2 gange øvre normalgrænse.
A total of 5.8% of patients experienced an elevation of indirect bilirubin of > 1 to 2 x ULN and 0.4% had an elevation of > 2 x ULN.
Samlet oplevede en højere andel af de patienter, som fik infliximab- monoterapi, en infusionsrelateret reaktion sammenlignet med patienter, som fik infliximab samtidig med immunmodulatorer.
Overall, a higher proportion of patients receiving infliximab monotherapy experienced an infusion-related reaction compared to patients receiving infliximab with concomitant immunomodulators.
Samlet overlevelse
Efficacy Parameter
Samlet overlevelse
Time to new treatment
Samlet overlevelse (død)
Overall survival (death)
Samlet overlevelse (endelig analyse)***
Overall Survival (final analysis)
Samlet overlevelse (followup-analyse)7
Overall Survival – Follow-up analysis7
Samlet overlevelse (måneder)
Overall survival (months)
Samlet overlevelse (måneder)
Overall Survival (OS) (months)
Samlet overlevelse (måneder) Antal forsøgspersoner i risikogruppe
Overall survival (Months)
Samlet overlevelse (OS)
Overall survival
Samlet overlevelse (OS) Måneder (median)
Overall Survival (OS) Months (median)
Samlet overlevelse (OS)***
Overall Survival (OS)
Samlet overlevelse (OS)b
Overall Survival (OS)b
Samlet overlevelse (OS)g
Overall Survivalg
Samlet overlevelse (primær analyse)6
Overall Survival – Primary analysis6
Samlet overlevelse (uge)
Overall Survival (Week)
Samlet overlevelse **
Overall Survival (OS)
Samlet overlevelse 12. januar 2015
Overall Survival 12 January 2015
Samlet overlevelse 13. marts 2015
Overall Survival 13 March 2015
Samlet overlevelse 13.marts 2015
Overall Survival 13 March 2015
Samlet overlevelse 3
Overall Survival 3
Samlet overlevelse 6
Overall survival 6
Samlet overlevelse efter 1 år (%)e 76,7 72,6
1-year Overall Survival (%)e 76.7 72.6
Samlet overlevelse for stadie 1a vises i figur 2.
Overall survival for Stage 1a is presented in Figure 2.
Samlet overlevelse for stadie 2 vil fortsat blive fulgt, da data endnu ikke er fuldstændige.
Overall survival for Stage 2 will continue to be followed and is not yet mature.
Samlet overlevelse hos platinsensitiv population (endelig analyse - n= 316 hændelser)
Overall survival in platinum-sensitive population (Final analysis n=316 events)
Samlet overlevelse i ITT- populationen
OS in ITT Population
Samlet overlevelse i PIX 301 ved studiets slutning
PIX 301 Overall survival–end of study
Samlet overlevelse kunne være ledsaget af bedring over tid af sygdomsrelaterede symptomer og ikke-sygdomsspecifik livskvalitet (QoL), som blev vurderet ved hjælp af valide og pålidelige skalaer i Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease Related Symptoms (FKSI- DRS) og EuroQoL EQ-5D.
Overall survival could be accompanied by an improvement over time in disease related symptoms and non-disease specific quality of life (QoL) as assessed using valid and reliable scales in the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) and the EuroQoL EQ-5D.
Samlet overlevelse var længere med ZYTIGA end med placebo med en 25 % reduktion af dødsrisiko (HR = 0,752; 95 % KI: [0,606; 0,934]; p=0,0097), men data for OS var ikke modne, og interimresultaterne opfyldte ikke den på forhånd specificerede stopgrænse for statistisk signifikans (se tabel 4).
Overall survival was longer for ZYTIGA than placebo with a 25% reduction in risk of death (HR = 0.752; 95% CI: [0.606; 0.934], p = 0.0097), but OS was not mature and interim results did not meet the pre-specified stopping boundary for statistical significance (see Table 4).
Samlet overlevelse ved år 1, 2 og 3 for Empliciti kombineret med lenalidomid- og dexamethason- var henholdsvis 91%, 73% og 60% sammenlignet med henholdsvis 83%, 69% og 53% ved lenalidomid- og dexamethason- (se figur 2).
The 1-, 2- and 3-year rates of overall survival for Empliciti in combination with lenalidomide and dexamethasone treatment were 91%, 73%, and 60% respectively, compared with 83%, 69%, and 53% respectively, for lenalidomide and dexamethasone treatment (See Figure 2).
Samlet overlevelse – sekundært endepunkt**
Overall Survival - secondary endpoint
Samlet overlevelse*
Overall survival
Samlet overlevelse*
Time to next therapy
Samlet overlevelse* Hændelser (dødsfald) n (%)
Overall survival* Events (deaths) n (%)
Samlet overlevelse*** (måneder)
OS*** (months)
Samlet overlevelse,
Overall survival
Samlet overlevelse, Median måneder
Overall Survival, Median months
Samlet overlevelse, n (%)
Overall survival, n (%)
Samlet overlevelse1
Overall Survival1
Samlet overlevelsea
Overall survivala
Samlet overlevelseb
Overall survivalb
Samlet overlevelsec
Overall survivalc
Samlet overlevelsec [median (95% CI)] måneder
Overall Survivalc [median (95% CI)] months
Samlet overlevelsed
Overall Survivald
Samlet overlevelsesanalyse ved klinisk cut-off 31. januar 2007
Overall survival analysis at clinical cut-off 31 January 2007
Samlet overlevelse– alle patienter
Overall Survival – All Patients
Samlet overlevelse– patienter med fjernmetastaser
Overall Survival – Patients with Distant Metastases
Samlet PANSS-score (Positive And Negative Syndrome Scale) for skizofreni - ændring fra baseline til endepunkt - LOCF for forsøgene R092670-SCH-201, R092670-PSY-3003, R092670-PSY-3004 og
Positive and Negative Syndrome Scale for Schizophrenia (PANSS) Total Score - Change From Baseline to End Point- LOCF for Studies R092670-SCH-201, R092670-PSY-3003, R092670-PSY-3004 and
Samlet PANSS-score – ændring fra baseline til uge 10: Analyse baseret på effektpopulationena
PANSS Total Score – Change From Baseline to Week 10: Randomised Efficacy Sample a
Samlet PANSS-score – ændring fra baseline til uge 38 (LOCF): Analyse baseret på effektpopulationen a, b
PANSS Total Score – Change From Baseline to Week 38-LOCF: Randomised Efficacy Sample a, b
Samlet population (n=300) 8,7 -0,7 -0,4 (-0,6; -0,2)2
Overall population (n=300) 8.7 -0.7 -0.4 (-0.6, -0.2)2
Samlet population (n=306) Baseline HbA1c ≥ 10 % strata (n=107)
Baseline HbA1c ≥ 10% stratum
Samlet population*
Overall population
Samlet rate for intrakraniel respons, % (95 % CI)a
Overall intracranial response rate,% (95% CI)a
Samlet respons %
Overall Response
Samlet respons (hiv 1-rna
Overall response (HIV-1 RNA
Samlet respons [N, %]
Overall response [n, %]
Samlet respons og en undergruppeanalyse af virologisk respons (< 50 hiv 1-rna-kopier/ml) ved både 48 uger og 96 uger samt virologisk svigt efter virusbelastning ved baseline (samlede data fra de to kliniske fase 3-studier, TMC278-C209 og TMC278-C215, for patienter, der fik BR FTC/TDF) præsenteres i tabel 4.
Overall response and a subgroup analysis of the virologic response (< 50 HIV-1 RNA copies/mL) at both 48 weeks and 96 weeks, and virologic failure by baseline viral load (pooled data from the two Phase 3 clinical studies, TMC278-C209 and TMC278-C215, for patients receiving the FTC/TDF BR) is presented in Table 4.
Samlet respons rate**
Overall response rate
Samlet respons, % (95 % CI)a
Overall response,% (95% CI)a
Samlet respons-grad
Overall Response Rate
Samlet respons-rate (CR+PR) (95 % CI) (%)c
Median PFS (95% CI) (months)
Samlet respons1 (n=118)
Overall Response1 (n=118)
Samlet respons1 (n=118)a
Overall Responsea (n=118)
Samlet respons: CR, VGPR eller PR
Overall response: CR, VGPR, or PR
Samlet responsa
Overall responsea
Samlet responsa (n=118)
Overall Responsea (n = 118)
Samlet responsa (n=118)
Overall Responsea (n=118)
Samlet responsrate
Overall response rate
Samlet responsrate (%)
Overall Response Rate (%)
Samlet responsrate (95 % CI) (%)
ORR (95% CI) (%)
Samlet responsrate (95% konfidensinterval)
Overall Response Rate (95% CI)
Samlet responsrate (Investigators vurdering)**
Overall response rate (invest. assessment)
Samlet responsrate = komplette + partielle respons.
Overall response rate = complete + partial responses.
Samlet responsrate inklusive PR med lymfocytosed (%)
Overall response rate including PR with lymphocytosisd (%)
Samlet responsrate ved uafhængig vurdering
Overall response rate by independent assessment
Samlet responsrate**
Overall response rate
Samlet responsrate, %
Overall Response Rate,
Samlet responsrate:
Overall Response Rate
Samlet responsratea %
Overall Response Ratea
Samlet responsratea (CR +PR)
Overall response ratea (CR +PR)
Samlet responsrated, e (%)
Overall response rated, e (%)
Samlet responsrate§
Overall response rate§
Samlet resumé af lægemiddelbivirkninger
Overall summary of adverse drug reactions
Samlet risiko ved 18 måneder (%)
Cumulative risk at 18 months (%)
Samlet set bidrog N-desmethylmetabolitten i gennemsnit mindre end 7 % (interval 4-9 %) til det lægemiddelstofrelaterede materiale i urin og fæces, som der kunne gøres rede for.
Overall, the N-desmethyl metabolite contributed a mean of less than 7% (range 4-9%) of the total medicinal product related material accounted for in the urine and faeces.
Samlet set bidrog N-desmetylmetabolitten i gennemsnit mindre end 6 % (interval 4-8 %) til det lægemiddelstofrelaterede materiale i urin og fæces, som der kunne redegøres for.
Overall, the N-desmethyl metabolite contributed a mean of less than 6 % (range 4-8 %) of the total topotecan related material accounted for in the urine and faeces.
Samlet set blev der ikke registreret væsentlige kliniske forskelle i sikkerhed og virkning mellem patienter ≥ 65 år og patienter < 65 år i NAPOLI-1-studiet, selv om seponering var hyppigere (14,8 % mod 7,9 %) i den førstnævnte gruppe, som blev behandlet med ONIVYDE + 5-FU/LV, og i nogle tilfælde forsvandt bivirkningerne ikke.
Overall, no major clinical differences in safety or efficacy were reported between patients ≥ 65 years and patients < 65 years, although a higher frequency of discontinuation (14.8% vs 7.9%) was noted in the former group treated with ONIVYDE+5-FU/LV in the NAPOLI-1 study and in some cases the adverse reactions did not resolve.
Samlet set for 11 studier med depotformulering af exenatid var de fleste episoder med hypoglykæmi (99,9 % n=649) milde og forsvandt efter oral administration af kulhydrater.
Across 11 studies of prolonged-release exenatide most episodes (99.9 % n=649) of hypoglycaemia were minor, and resolved with oral administration of carbohydrate.
Samlet set havde 6 % af patienterne inflammatorisk brystkræft, 25 % havde lokalt avanceret brystkræft, og 69 % havde operabel brystkræft.
Overall 6% of patients had inflammatory breast cancer, 25% had locally advanced breast cancer and 69% had operable breast cancer.
Samlet set havde 7 % af patienterne inflammatorisk brystkræft, 32 % havde lokalt avanceret brystkræft, og 61 % havde operable brystkræft.
Overall 7% of patients had inflammatory breast cancer, 32% had locally advanced breast cancer and 61% had operable breast cancer.
Samlet set indikerer disse data ikke en betydelig stigning i risikoen for alvorlige medfødte misdannelser, selvom teratogen risiko ikke kan udelukkes fuldstændigt.
Overall, these data do not suggest a substantial increase in the risk for major congenital malformations, although a teratogenic risk cannot be completely excluded.
Samlet set medførte XGEVA objektiv tumorrespons hos 71,6% (95% CI 64,6; 77,9) af patienterne (tabel 3), vurderet med en hvilken som helst af modaliteterne, hvor størstedelen af responserne var defineret som en reduktion i fluordeoxyglucose-PET-aktivitet eller en stigning i densitet, målt i CT/HU; kun 25,1% af patienterne havde respons i henhold til RECIST-kriterierne.
Overall, XGEVA achieved objective tumour responses in 71.6% (95% CI 64.6, 77.9) of patients (table 3) ) assessed by any of the modalities, with the majority of responses defined by a reduction in fluorodeoxyglucose PET activity or increase in density measured in CT/HU, only 25.1 % of the patients had a response per RECIST.
Samlet set opnåede en signifikant højere andel af eltrombopagpatienterne (40 %) sammenlignet med placebopatienterne (3 %) det primære endepunkt (Odds Ratio: 18,0 [95 % CI: 2,3; 140,9] p < 0,001), og resultaterne var omtrent ens på tværs af de tre alderskohorter (tabel 6).
Overall, a significantly greater proportion of eltrombopag subjects (40%) compared with placebo subjects (3%) achieved the primary endpoint (Odds Ratio: 18.0 [95% CI: 2.3, 140.9] p < 0.001) which was similar across the three age cohorts (Table 6).
Samlet set opnåede en signifikant højere andel af eltrombopagpatienterne (62 %) sammenlignet med placebopatienterne (32 %) det primære endepunkt (Odds Ratio: 4,3 [95 % CI: 1,4; 13,3] p = 0,011).
Overall, a significantly greater proportion of eltrombopag subjects (62%) compared with placebo subjects (32%) met the primary endpoint (Odds Ratio: 4.3 [95% CI: 1.4, 13.3] p=0.011).
Samlet set peger de oplysninger, der kommer fra post-marketing erfaring, fra tilfælde med kort tid til hændelsen indtraf, kompatibel kronologi, og information om de-challenge og re-challenge tilfælde og veldokumenterede rapporter, i retning af en årsagssammenhæng.
Overall, the information coming from post-marketing experience, cases with short time to onset, compatible chronology, and information of de-challenge and re-challenge cases and the well documented reports, point towards a causal association.
Samlet set steg Cmax og AUC nogenlunde proportionalt med dosis i det undersøgte dosisinterval (120 mg til 360 mg).
Overall, Cmax and AUC increased approximately dose- proportionally in the dose range studied (120 mg to 360 mg).
Samlet set svarede sikkerhedsprofilen hos patienter, der var co-inficeret med hepatitis B- og/eller C-virus, til den sikkerhedsprofil, der blev observeret hos patienter uden co-infektion med hepatitis B- eller C-virus, selvom raterne af ASAT- og ALAT- abnormaliteter var højere i undergruppen med co-infektion med hepatitis B- og/eller C-virus for alle behandlingsgrupper.
Overall, the safety profile in patients co-infected with hepatitis B and/or C was similar to that observed in patients without hepatitis B or C co-infection, although the rates of AST and ALT abnormalities were higher in the subgroup with hepatitis B and/or C co-infection for all treatment groups.
Samlet set svarede sikkerhedsprofilen hos patienter, der var co-inficeret med hepatitis B- og/eller C-virus, til den sikkerhedsprofil, der blev observeret hos patienter uden co-infektion med hepatitis B- eller C-virus, selvom raterne af ASAT- og ALAT-abnormaliteter var højere i undergruppen med co-infektion med hepatitis B- og/eller C-virus for alle behandlingsgrupper.
Overall, the safety profile in patients co-infected with hepatitis B and/or C was similar to that observed in patients without hepatitis B or C co-infection, although the rates of AST and ALT abnormalities were higher in the subgroup with hepatitis B and/or C co-infection for all treatment groups.
Samlet set tyder de få rapporter fra alle studier på, at patienter ikke har en øget risiko for at udvikle autoimmune hændelser ved langvarig belatatacept- eksponering.
Overall, the few reports across clinical studies suggest that prolonged exposure to belatacept does not predispose patients to an increased risk of development of autoimmune events.
Samlet set var 58% af alle patienter, der var inkluderet i studiet, seropositive for vildtype-HSV-1 ved baseline, og 32,6% var seronegative; de resterende 9,4%’s HSV- 1-serostatus var ukendt.
Overall, 58% of all patients enrolled into the study were seropositive for wild-type HSV-1 at baseline and 32.6% were seronegative; the HSV-1 serostatus of the remaining 9.4% was unknown.
Samlet set var clopidogrel 75 mg/dag sammenligneligt med ASA 325 mg/dag i CAPRIE uden hensyntagen til alder, køn eller race.
Overall, clopidogrel 75 mg/day was comparable to ASA 325 mg/day in CAPRIE regardless of age, gender and race.
Samlet set var gennemsnitsalderen af patienterne 11,8 år med 48,6% af patienter i aldersgruppen 6- 11 år og 51,4% i aldersgruppen 12-17 år.
Overall, the mean age of the patients was 11.8 years with 48.6% of patients being in the 6-11 years age group and 51.4% in the 12-17 years age group.
Samlet set var ruxolitinibs farmakodynamiske aktivitet lignende, hvilket tyder på, at CYP3A4- induktionen medførte en minimal farmakodynamisk effekt.
Overall, the ruxolitinib pharmacodynamic activity was similar, suggesting the CYP3A4 induction resulted in minimal effect on the pharmacodynamics.
Samlet set var sikkerhedsprofilen blandt disse 227 børn den samme som blev set i den voksne population.
Overall, the safety profile in these 227 children was similar to that observed in the adult population.
Samlet set var sikkerhedsprofilen for T/LAIV hos et begrænset antal forsøgspersoner med let til moderat ikke-hiv-relateret kompromitteret immunfunktion, asymptomatisk eller let symptomatisk hiv-infektion eller cancer (solide tumorer og hæmatologiske maligniteter) sammenlignelig med sikkerhedsprofilen for raske personer og indikerede ingen problematiske virkninger.
Overall, the safety profile of T/LAIV in a limited number of subjects with mildly to moderately non- HIV related compromised immune function, asymptomatic or mildly symptomatic HIV infection, or cancer (solid tumors and haematological malignancies) was comparable to that in healthy individuals and does not indicate any untoward effect.
Samlet stadie 1 & 2
Pooled Stages 1 & 2
Samlet svarede sikkerhedsprofilen for Revestive hos børn og unge (i alderen 1-17 år) til sikkerhedsprofilen hos voksne.
Overall, the safety profile of Revestive in children and adolescents (ages 1-17 years) was similar to that in adults.
Samlet SVR12
responder
Samlet SVR12 209/210 99,5 98,6; 100,0 209/209 100 98,2; 100,0
Overall SVR12 209/210 99.5 98.6, 100.0 20 100 98.2, 100.0
Samlet SVR12 456/473
Overall SVR12 456/473
Samlet SVR12-ratea
Overall SVR12 ratea
Samlet SVRd
Overall SVR d
Samlet var omfanget af personer med en 50 % reduktion i hyppigheden af anfald 23%, 34% og 40% for placebo, lacosamid 200 mg/dag og lacosamid 400 mg/dag.
Overall the proportion of subjects with a 50% reduction in seizure frequency was 23%, 34%, and 40% for placebo, lacosamide 200 mg/day and lacosamide 400 mg/day.
Samlet var rapporterne mere almindelig efter intravenøs administration.
Overall, reports were more common after intravenous administration.
Samlet var sikkerheden og tolerabiliteten ved Cinryze sammenlignelig for børn og voksne.
Overall, the safety and tolerability of Cinryze are similar in children and adults.
Samlet vedvaren- de respons
Overall Sustained Response
Samlet velaglucerase
Overall
Samlet virkning af posaconazol oral suspension efter endt behandling af invasiv aspergillose sammenlignet med en ekstern kontrolgruppe
Overall efficacy of posaconazole oral suspension at the end of treatment for invasive aspergillosis in comparison to an external control group
Samlet volumen af opblandet suspension, som skal fremstilles
Total volume of compounded suspension to be prepared
Samlet* ITT
Overall* ITT
Samlet, % (95 % CI) Major, % (95 % CI)
Overall, % (95% CI) Major, % (95% CI)
Samleta
Overalla
Samletc
Overallc